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ABSTRACT: Previous experiments in suitable animal models and in mild hypercholesterolemic individuals have shown that the
consumption of lupin proteins may be useful for controlling total and low-density lipoprotein (LDL) cholesterol levels. With the
objective of providing evidence that peptides deriving from the hydrolysis of lupin proteins may be responsible of the observed
activities and for investigating the mechanism of action, HepG2 cells were treated with lupin peptides obtained by either pepsin
(P) or trypsin (T) hydrolysis, and molecular and functional investigations were performed on the LDL receptor/SREBP2
pathway. For the ﬁrst time, this paper provides experimental evidence that lupin peptides are able to interfere with the
HMGCoAR activity, up-regulating the LDL receptor (136 and 84% vs the control for P and T peptides, respectively, at 1 mg/mL)
and SREBP2 proteins (148 and 73% vs the control for P and T peptides, respectively, at 1 mg/mL) via the activation of PI3K/Akt/
GSK3β pathways and increasing the LDL uptake at HepG2 cell line (40 and 50% vs the control for P and T peptides, respectively, at
1 mg/mL). These results may be useful in explaining the activities observed in vivo in animals and humans treated with lupin
protein.
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■ INTRODUCTION
Lupin is a protein-rich grain legume, which has been domesticated
for a long time and cultivated on diﬀerent continents, for either
animal or human nutrition. This generic term indicates four species:
Lupinus albus (white lupin), Lupinus angustifolius (narrow-leaf
lupin), Lupinus luteus (yellow lupin), and Lupinus mutabilis
(Andean lupin). The seeds of these plants have some favorable
features; in particular, the protein percentage is comparable to that
of soybean,1 and the content of indispensable amino acids is only
slightly inferior. Lupin is also a good source ofminerals,1 unsaturated
fatty acids,2 vitamins,1 and tocopherols,3 whereas the concentrations
of isoﬂavones4 and other antinutrients are low.5 Experiments in rats
have shown that the nutritional quality of L. albus protein is
satisfactory.6 Old species contained undesirable quinolizidine
alkaloids that in modern cultivars were decreased to very low
amounts,7 permitting the direct use of these seeds for diﬀerent
applications.8,9
Besides these important nutritional features, lupin seed may
also provide some health beneﬁts, particularly in the area of
hypertension10 and dyslipidemia prevention. Some investiga-
tions in a rat model of hypercholesterolemia have demonstrated
that diets containing either L. albus protein11,12 or L. angustifolius
protein13,14 may signiﬁcantly reduce both total cholesterol and
low-density lipoprotein cholesterol (LDL-C) levels versus
control diets containing casein. The cholesterol-lowering activity
of L. albus has also been conﬁrmed in a hamster model of
dyslipidemia.15 Moreover, in a rabbit model of atheromatous
plaque, L. albus protein has slowed plaque formation induced by
a hyperlipidemic diet.16 Finally, an uncontrolled clinical trial on
L. albus17 and two controlled on L. angustifolius18,19 have
conﬁrmed the hypocholesterolemic activity in humans. Despite
these positive results, however, only very scarce data are available
either on the mechanism of action or on the actual bioactive
component(s) in lupin.
The favorable eﬀects of plant proteins in cardiovascular
prevention is well established; the ﬁrst study on the hypo-
cholesterolemic activity of soybean dates back to the 1970s.20
Some relevant reviews and meta-analyses21−23 summarize the
numerous trials performed in the following years. In 1999 the
U.S. Food and Drug Administration approved the health claim
on the role of soybean protein in reducing the risk of
cardiovascular disease.24 The literature on soy may thus provide
mechanistic information that may be also relevant in the case of
other plant proteins, such as lupin. Studies in animal models and
humans have demonstrated that the hypocholesterolemic eﬀects
of soy are due to the activation of LDL receptors (LDLR) that are
relevant in the metabolic degradation of LDL-C. Soy protein was
able to reverse the dramatic down-regulation of liver LDLR
observed in rats on cholesterol/cholic acid dietary regimens
versus casein,25 and the expression of LDLR was increased in
patients aﬀected by familial hypercholesterolemia26 and in
moderately hypercholesterolemic individuals.27 In parallel, in
vitro and in vivo experiments have demonstrated that some
Received: February 19, 2014
Revised: June 19, 2014
Accepted: June 27, 2014
Article
pubs.acs.org/JAFC
© XXXX American Chemical Society A dx.doi.org/10.1021/jf500795b | J. Agric. Food Chem. XXXX, XXX, XXX−XXX
speciﬁc soy peptides are responsible for the LDLR modu-
lation.28−32 Nevertheless, the mechanism at the molecular level
has not been investigated in detail yet. These bioactive peptides,
initially encrypted in the soy protein sequences, are probably
enzymatically released during digestion and absorbed.33
The majority of plasma cholesterol is transported by the LDL
fraction, and the cellular uptake of LDL is mediated by the
LDLR. The circulating level of LDL is determined in large part by
its rate of uptake through the hepatic LDLR pathway.34,35
Moreover, the LDLR plays a crucial role in Apo B turnover, being
involved in determining the post-translation fate of apoB by
increasing presecretory apoB degradation and mediating
re-uptake of nascent lipoprotein particles.36 In general, LDLR
expression is ﬁnely tuned by changes in intracellular cholesterol.37
A transcription factor known as the sterol-responsive element
binding protein 2 (SREBP2) plays a critical role in LDLR mRNA
expression.38,39 Among SREBP2 gene targets, the 3-hydroxy-3-
methylglutaryl coenzyme A (HMGCoA) reductase (HMGCoAR)
is particularly important. This enzyme plays a key role in the intra-
cellular cholesterol biosynthesis, because it is the rate-controlling
enzyme in the mevalonate pathway. After synthesis, SREBP2 forms
a complex with the SREBP cleavage-activating protein (SCAP) and
is localized in the endoplasmic reticulum (ER) as an inactive
precursor (pro-SREBP2). Sterol deﬁciency results in the release of
SREBP2/SCAP complex fromER and transport to theGolgi, where
pro-SREBP2 is processed further, allowing the N-terminal fragment
(mature SREBP2) to enter the nucleus and up-regulate tran-
scription of LDLRandHMGCoAR.40 In addition to SREBP2, other
transcription factors may be involved in a context-dependent
fashion in regulating the LDLR expression.
Recent studies41,42 identify a crucial signaling pathway, via
phosphatidylinositol-3-kinase (PI3K)/Akt, as an important
player in the regulation of cellular lipid metabolism. This
pathway is the best known for its role in promoting cell growth,
proliferation, and survival through increased glucose utilization
and prevention of apoptosis.43,44 In particular, Akt has recently
been implicated in a novel form of lipid metabolism regulation,
through the SREBPs.45 The physiological coordination between
Akt and SREBPs pathways is needed to produce the lipids for
new membrane synthesis, which in turn is required for growing
and proliferating cells.41,42 Even though many studies have been
focused on the SREBP-1c isoform,45 new eﬀorts are directed to
explore and to investigate the link between Akt and SREBP2.41,46
The objective of the present study was to characterize in detail
the molecular mechanism at the basis of the cholesterol-lowering
properties of L. albus protein observed in experimental and
clinical investigations. On the basis of the hypothesis that the
activity may depend on speciﬁc peptides encrypted in the protein
sequences, a total protein extract from lupin seed was hydrolyzed
either with pepsin (P peptides) or with trypsin (T peptides). The
HepG2 cell line was treated with both kinds of peptides, and
molecular and functional investigations were performed on the
LDLR-SREBP2 and PI3K/Akt pathways, using a combination of
techniques.
■ MATERIALS AND METHODS
Chemicals. Dulbecco’s modiﬁed Eagle’s medium (DMEM),
L-glutamine, fetal bovine serum (FBS), phosphate-buﬀered saline (PBS),
penicillin/streptomycin, chemiluminescent reagent, and 96-well plates were
purchased from Euroclone (Milan, Italy). Bovine serum albumin (BSA),
RIPA buﬀer, HMGCoAR Assay Kit, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), and wortmannin were from
Sigma-Aldrich (St. Louis, MO, USA). Antibodies against HMGCoAR
were bought from Abcam (Cambridge, UK). Antibodies against β-actin,
SREBP-2, rabbit Ig-HRP, and mouse Ig-HRP, PMSF, sodium
orthovanadate inhibitors, and goat anti-rabbit Ig-HRP were purchased
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Antibodies
against the LDL receptor were from Pierce (Rockford, IL, USA). The
inhibitor cocktail Complete Midi was from Roche (Basel, Switzerland).
Mini protean TGX precast gel 7.5% andMini nitrocellulose Transfer Packs
were purchased fromBio-Rad (Hercules, CA,USA). LDL-DyLight 549was
from Cayman Chemical (Ann Arbor, MI, USA).
Preparation and Analysis of the Pepsin and Trypsin Peptide
Mixtures. Lupin seeds of the species L. albus (cultivar Ares) were
provided by Terrena (Matrigne-̀Ferchaud, France). The total protein
extracts were obtained as previously reported.47 Brieﬂy, proteins were
extracted from defatted ﬂour with 100 mM Tris-HCl/0.5 M NaCl buﬀer,
pH 8.2, for 2 h at 4 °C. The solid residue was eliminated by centrifugation at
6500g, for 20min at 4 °C, and the supernatant was dialyzed against 100mM
Tris-HCl buﬀer, pH 8.2, for 24 h at 4 °C. The protein content was assessed
according to the method of Bradford, using BSA as standard.
For the hydrolysis, the total protein extract was initially dissolved in
Tris-HCl buﬀer 100 mM at pH 8, and then the pH was adjusted to the
optimal hydrolysis conditions for each enzyme (pH 2 for pepsin and pH
8 for trypsin) by adding 1 M NaOH or 1 M HCl. The mixtures were
incubated for 18 h, then the enzymes were inactivated, and the mixtures
were puriﬁed by ultraﬁltration through 3000 Da cutoﬀ centrifuge ﬁlters
(Amicon Ultra-0.5, Millipore, Billerica, MA, USA) at 12000g for 30 min
at 4 °C. The peptide concentration in the permeates was measured
according to a literature method,48 based on chelating the peptide bonds
by Cu(II) in alkaline media and monitoring the change of absorbance at
330 nm. Details are reported in a previous paper.47
The hydrolyzed mixtures were acidiﬁed with formic acid to a ﬁnal
10% concentration. Eight microliters of tryptic digest for each band was
injected in a nanochromatographic system, UltiMate 3000 RSLC nano-
System (Thermo Scientiﬁc). The peptide mixtures were loaded on a
reversed-phase trap column (Acclaim PepMap100, C18, 100 Å, 100 μm
i.d. × 2 cm, Thermo Scientiﬁc) for the cleanup and preconcentration.
After cleanup, the valve was switched to place the trap column in series
with a fused silica reverse-phase column (picoFrit column, C18, 2.7 μm,
New Objective). The peptides were eluted with a 30 min gradient from
4% buﬀer A (2% acetonitrile and 0.1% formic acid in water) to 60%
buﬀer B (2% water and 0.1% formic acid in acetonitrile) at a constant
ﬂow rate of 300 nL/min. The chromatographic column was directly
connected to an LTQ-XL mass spectrometer (Thermo Scientiﬁc)
equipped with a nano spray ion source. Full scan mass spectra were
acquired in the mass range from m/z 350 to 2000 Da, and the ﬁve most
intense ions were automatically selected and fragmented in the ion trap.
Target ions already selected for mass spectrometry (MS/MS) were
dynamically excluded for 30 s. The MS data were analyzed separately by
Mascot search engine (version 2.3.01) using Proteome Discover
software (v. 1.2.0 Thermo) and consulting Uniprot_viridiplantae
(30,264 sequences, 184,678,199 residues). Oxidation of methionine
residues was set as variable modiﬁcations; two missed cleavages were
allowed to trypsin; peptide mass tolerance was set to 1 Da and fragment
mass tolerance to 0.8 Da; and an ion source cutoﬀ of 20 was chosen. The
false discovery rate obtained by Proteome Discoverer, consulting the
Mascot decoy database, was <0.01. Tables 1S and 2S in the Supporting
Information list the proteins and the unmatched peptides, with all
relevant peptide signals, peptide sequences, ion score, variable
modiﬁcations and mass errors.
Cell Culture Conditions. HepG2 cell line was bought from ATCC
(HB-8065, ATCC from LGC Standards, Milan, Italy). The HepG2 cell
line was cultured in DMEM high-glucose with stable L-glutamine
supplemented with 10% FBS, 100 U/mL penicillin, and 100 μg/mL
streptomycin (complete growth medium) and incubated at 37 °C under
5% CO2 atmosphere. HepG2 cells were used for no more than 20
passages after thawing because the increase of the number of passages
may change the cell characteristics and impair assay results.
MTT. HepG2 cells (3 ×104/well) were seeded in 96-well plates and
treated with 0.3, 0.5, 1.0, 2.5, 5.0, and 10.0 mg/mL of P and T peptides,
respectively, or vehicle (100 mMTris) in complete growth media for 48 h.
Subsequently, the treatment solventwas aspirated and 100μL/well ofMTT
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ﬁltered solution added for 48 h. After the incubation time, 0.5mg/mLMTT
solution was aspirated and 100 μL/well of MTT lysis buﬀer (8 mMHCl +
0.5%NP-40 in DMSO) added. After 5 min of slow shaking, the absorbance
at 575 nm was read on an LT 4000 spectrophotometer.
HMGCoAR Activity Assay. The assay buﬀer, the NADPH, the
substrate solution, and the HMG-CoA reductase were provided in the
HMGCoAR Assay Kit (Sigma). The experiments were carried out
following the manufacturer’s instructions at 37 °C. In particular, each
reaction (200 μL) was prepared by adding the reagents in the following
order: 1× assay buﬀer; 0.1, 0.25, 0.5, 1.0, and 2.5 mg/mL of T peptides
or 0.5, 1.0, and 2.5 mg/mL of P peptides or vehicle (C); NADPH
(4 μL); substrate solution (12 μL); and ﬁnally HMG-CoA reductase
Figure 1.Nano-LCMS/MS of lupin peptide mixtures: (A, B) chromatogram and full scan mass spectrum of T peptides; (C, D) chromatogram and full
scan mass spectrum of P peptides.
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(catalytic domain) (2 μL). Subsequently, the samples were mixed and
the absorbance at 340 nm read by a Synergy H1 microplate reader from
Biotek at times 0 and 10 min. The HMGC-CoA-dependent oxidation of
NADPH and the inhibition properties of lupin peptides were measured
by the absorbance reduction, which is directly proportional to the
enzyme activity.
Western Blot Analysis.HepG2 cells (1.5 × 105/well, 24-well plate)
were treated with 0.5, 1, and 2.5 mg/mL of P and T peptides for 24 h.
For the experiments in the presence of wortmannin, cells were treated
with 1 mg/mL P and 0.5 mg/mL T peptides in the presence or absence
of 1 μM inhibitor for 24 h. After each treatment, cells were scraped in
40 μL of ice-cold lysis buﬀer (RIPA buﬀer + inhibitor cocktail +
1:100 PMSF + 1:100 sodium orthovanadate) and transferred in an ice-
cold microcentrifuge tube. After centrifugation at 13300 rpm for 15 min
at 4 °C, the supernatant was recovered and transferred into a new ice-
cold tube. Total proteins were quantiﬁed according to the Bradford
method, and 50 μg of total proteins was loaded on a precast 7.5% sodium
dodecyl sulfate−polyacrylamide (SDS-PAGE) gel at 130 V for 45 min.
Subsequently, the gel was pre-equilibrated with 0.04% SDS in H2O
for 15 min at room temperature and transferred to a nitrocellulose
membrane (Mini nitrocellulose Transfer Packs,) using a Trans-blot
Turbo at 1.3 A and 25 V for 7 min. Target proteins, on milk-blocked
membrane, were detected by primary antibodies as follows: rabbit anti-
SREBP2, rabbit anti-LDLR, anti-HMGCoAR, antipospho-Akt (ser473),
antipospho-GSK3α/β (ser21/ser9), and anti-β-actin. Secondary anti-
bodies conjugated with HRP and a chemiluminescent reagent were used
to visualize target proteins, and their signal was quantiﬁed using ImageJ
software. The internal control, β-actin, was used to normalize loading
variations. In the case of SREBP2, the band at 70 kDa, corresponding to
the N-terminal fragment (mature SREBP2 protein), was detected and
quantiﬁed.
Fluorescent LDL Uptake Cell-Based Assay. HepG2 cells
(3 ×104/well) were seeded in 96-well plates and kept in complete
growth medium for 2 days before treatment. The third day, cells were
treated with 1.0 mg/mL P peptides and 0.25 mg/mL T peptides,
respectively, or vehicle (100 mM Tris) for 24 h. For the experiments in
the presence of the PI3K inhibitor,HepG2 cells were treatedwith 1.0mg/mL
P peptides and 0.5 mg/mLT peptides in the presence or absence of 100 nM
wortmannin and in the presence of the only inhibitor, as control, in
DMEM without FBS for 24 h. At the end of the treatment periods,
the culture medium was replaced with 75 μL/well LDL-DyLight
549 working solution. The cells were additionally incubated for 2 h at
37 °C, and then the culture medium was aspirated and replaced with
PBS 100 μL/well. The degree of LDL uptake was measured using the
Synergy H1 ﬂuorescent plate reader from Biotek (excitation and
emission wavelengths 540 and 570 nm, respectively).
Statistical Analysis. Statistical analyses were carried out by one-way
ANOVA (Graphpad Prism 6) followed by Dunnett’s test. Values were
expressed as means ± SEM; P values <0.05 were considered to be
signiﬁcant.
■ RESULTS
Preparation and Analysis of the Peptide Mixtures. A
total protein extract from lupin seed was hydrolyzed with pepsin
and trypsin to produce P peptides and T peptides, respectively.
The two samples were analyzed by nano-LC-MS/MS. The
chromatograms (Figure 1) showed two diverse proﬁles due to
the diﬀerent peptide compositions of the digested samples.
The number of potentially bioactive peptides is very high
in both samples, because more than 2000 peptides were
detected in the pepsin-digested mixture and about 3000 in the
trypsin-digested one (Tables 1S and 2S in the Supporting
Information).
It was possible to assign only a small number of peptides to
known lupin proteins by Mascot software consulting the
Uniprot_viridiplantae database. The other peptides were
sequenced, but not assigned to protein hits, possibly due to the
very incomplete sequencing of lupin proteins. The recognized
peptides in the P sample belong to the main storage proteins
in lupin seed: 21 peptides to the vicilins [L. albus vicilin-
like protein (Q53HY0) and L. albus β-conglutin (Q6EBC1)];
7 peptides to the legumins [L. angustifolius conglutin-α
3 (F5B8V8)], and 8 peptides to γ-conglutin [L. albus
conglutin-γ (Q9FSH9)], a sulfur-rich basic protein typical of
lupin (4−5%).
The identiﬁed peptides in the T sample are the following:
16 peptides belong to the vicilins [L. albus vicilin-like
protein (Q53HY0), L. albus β-conglutin precursor (Q6EBC1),
and L. angustifolius conglutin β (B0YJF8)]; 4 to the legumins
[L. angustifolius legumin-like protein (Q53I55)], and 2 to
δ-conglutin, a 2S protein [L. albus conglutin δ seed storage
protein precursor (Q99235)]. Two peptides were assigned
to other plant proteins, probably because the lupin sequences
are not present in the database: Zea mays actin partial (ADF3).
HepG2 Cell Viability.MTT experiments were performed to
exclude the peptide doses with potential toxic eﬀects on the
HepG2 cell line. No signiﬁcant cell mortality was observed up to
2.5 mg/mL after a 48 h treatment versus vehicle (C, 100 mM
Tris), suggesting that neither P nor T peptides induce cell
mortality in this dose range, whereas about 20 and 80% cell
mortalities were observed at 5.0 and 10 mg/mL, respectively
(Figure 2). For this reason, all of the following experiments,
aimed at investigating the molecular and functional eﬀects of
P and T peptides, were conducted using doses of ≤2.5 mg/mL.
Eﬀects of P and T Peptides on the Catalytic Domain of
HMGCoAR. To check the direct ability of P and T peptides to
inhibit HMGCoAR, an in vitro assay was performed using the
puriﬁed catalytic domain of this enzyme. Both P and T peptides
Figure 2. HepG2 cell viability after P and T peptide treatment. Bar
graphs indicate the results of MTT cell viability assay of HepG2 cells after
P andT peptide treatment for 48 h.Data points represent averages± SEM
of three independent experiments in triplicate. (∗∗) P < 0.001 and (∗∗∗)
P < 0.0001 versus C. P, pepsin peptides; T, trypsin peptides; C, control.
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were capable of inhibiting HMGCoAR, but with very diﬀerent
activities and potencies (Figure 3). In fact, P peptides inhibited
the enzyme with a statistical signiﬁcance (−17%) only at the
maximum tested dose (2.5 mg/mL), whereas they are ineﬀective
at 0.5 and 1.0 mg/mL. On the contrary, T peptides showed a
statistically signiﬁcant reduction of the HMGCoAR activity at all
tested doses: in fact, the enzyme activity was reduced by 37% at
0.25 mg/mL, by 57% at 0.5 mg/mL, and by 61% at 1.0 and
2.5 mg/mL.
Lupin Peptides Mediate the Up-regulation of LDLR-
SREBP2 at HepG2 Cells. HepG2 cells were treated for 24 h
with P and T peptides at concentrations of 0.5, 1.0, and 2.5 mg/mL.
Immunoblotting experiments showed that the treatments with lupin
peptides induce an up-regulation of the SREBP2 protein level. In
particular, P peptides up-regulate the SREBP2 protein level by 100,
148, and 162% versus the control, whereas T peptides increase the
SREBP2 protein level by 80, 73, and 44% versus the control, after
0.5, 1.0, and 2.5 mg/mL treatments, respectively (Figure 4B).
In the same experiments, also the LDLR and HMGCoAR
protein levels were measured by immunoblotting. Figure 4C
shows that both P and T peptides are able to induce a statistically
signiﬁcant up-regulation of LDLR protein inHepG2 cells versus the
control, but with diﬀerent behaviors. In particular, at 0.5, 1.0, and 2.5
mg/mL P peptides mediate 147, 136, and 120% inductions of the
LDLRprotein, whereasTpeptidesmediate a∼85%up-regulation at
0.5 and 1.0 mg/mL and a 61% up-regulation at 2.5 mg/mL versus
the control (Figure 4C). These results are in agreement with the up-
regulation of SREBP2 protein level.
Both P and T peptides aﬀect the HMGCoAR levels (Figure 4D),
but with very diﬀerent behaviors and activities. Precisely, P peptides
increase the synthesis of HMGCoAR by 82% at 0.5 mg/mL, by
212% at 1.0 mg/mL, and by 340% at 2.5 mg/mL versus the control,
that is, in a dose-dependent manner. On the contrary, treatment
with T peptides enhances the production of HMGCoAR by 233%
at 0.5 mg/mL and by only 97% at 1.0 mg/mL, whereas it is
practically inactive at 2.5 mg/mL.
Figure 3. Lupin peptide eﬀect on the catalytic domain of HMGCoAR.
Bars indicate the eﬀects of P peptides (0.5, 1.0, and 2.5 mg/mL) (A) and
T peptides (0.25, 0.5, 1.0, and 2.5 mg/mL) (B) on HMGCoAR activity.
HMGCoAR, physiologically, catalyzes the four-electron reduction of
HMG-CoA to coenzyme A (CoA) and mevalonate (HMG-CoA +
2NADPH+ 2H+ >mevalonate + 2NADP+ + CoA-SH). In this assay, the
decrease in absorbance at 340 nm, which represents the oxidation of
NADPH by the catalytic subunit of HMGCoAR in the presence of the
substrate HMG-CoA, was measured spectrophotometrically. Data
points represent averages ± SEM of three independent experiments
in triplicate. (∗∗) P < 0.001 and (∗∗∗) P < 0.0001 versus C. P, pepsin
peptides; T, trypsin peptides; C, control.
Figure 4. Eﬀect of P and T peptides on the SREBP2, LDLR, and HMGCoAR protein levels. HepG2 cells (1.5 × 105) were treated with 0.5, 1.0, and 2.5
mg/mL of P and T peptides for 24 h, respectively. SREBP2, LDLR, HMGCoAR, and β-actin immunoblotting signals were detected using speciﬁc anti-
SREBP2, anti-LDLR, anti-HMGCoAR, and anti-β-actin primary antibodies, respectively (A). SREBP2 (B), LDLR (C), and HMGCoAR (D) signals
were quantiﬁed by ImageJ software and normalized with β-actin signals. Bars represent averages of duplicate samples ± SEM of three independent
experiments. (∗) P < 0.05 and (∗∗) P < 0.001 versus C. P, pepsin peptides; T, trypsin peptides; C, control.
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Lupin Peptides Increase LDL Uptake at the HepG2 Cell
Line. Fluorescent LDL uptake experiments were performed for
evaluating the cholesterol-lowering properties of lupin peptides
from a functional point of view. Precisely, the ﬂuorescent LDL
uptake was examined in HepG2 cells following a 24 h incubation
with P and T peptides. Figure 5 shows that both P and T peptides
are able to increase the LDL uptake versus the control in a
statistically signiﬁcant way. In particular, treatment with P
peptides at concentrations of 1.0 and 2.5 mg/mL increases the
LDL uptake by 42 and 45%, respectively, versus the control,
whereas the LDL uptake increase was not statistically signiﬁcant
at 0.5 mg/mL. On the other hand, at concentrations of 0.25, 0.5,
and 1.0 mg/mL T peptides signiﬁcantly raise the LDL uptake by
52, 50, and 70%, respectively, versus the control.
Lupin Peptides Mediate LDLR-SREBP2 Up-regulation
through the Activation of PI3K/Akt/GSK3β Kinases. To
examine the eﬀect of lupin peptides on the activation of Akt and
GSK3β (its direct substrate), immunoblot analyses were
performed on lysates from treated HepG2 cells using antibodies,
which are speciﬁc for Akt phosphorylated at serine residue 473
and for GSK3β phosphorylated at serine residue 9. In accordance
with the preceding immunoblot experiments, HepG2 cells were
treated with P and T peptides at concentrations of 1.0 and 0.5
mg/mL, and the variation of phosphorylated Akt and GSK3β
levels was investigated. Figure 6B shows that the treatments with
lupin peptides increased the Akt phosphorylation in a dose-
dependent manner: by 92 and 125%, respectively, after treatment
with P peptides at 0.5 and 1.0 mg/mL and by 144 and 196%,
respectively, after treatment with T peptides at 0.5 and 1.0 mg/mL.
Additionally, P peptides mediate a 60% increase of the
phosphorylation level of GSK3β at 0.5 mg/mL and a 74%
increase at 1.0 mg/mL versus the control. After T peptide
treatments, instead, the GSK3β phosphorylation level was increased
by 133% at 0.5mg/mL and by only 75% at 1.0mg/mL (Figure 6D).
Treatment with 1 μMwortmannin, a PI3K inhibitor, inhibited
the Akt phosphorylation either in the presence or in the absence
of both lupin peptide mixtures. Figure 7A shows a representative
immunoblot and the relative intensity of the phospho-Akt bands.
The quantiﬁcation and normalization against actin bands from
Figure 5. LDL uptake after P and T peptide treatments. HepG2 cells
(3× 104) were treated with P (0.5, 1.0, and 2.5 mg/mL) and T (0.25, 05,
and 1.0 mg/mL) peptides for 24 h. LDL-Dylight 549 (10.0 μg/mL) was
incubated for an additional 2 h. Excess LDL-Dylight 549 was removed,
cells were washed two times with PBS, and speciﬁc ﬂuorescent LDL
uptake was analyzed by Synergy H1 (Biotek). Data points represent
averages ± SEM of three independent experiments in triplicate. (∗) P <
0.05 and (∗∗) P < 0.001 versus C. P, pepsin peptides; T, trypsin
peptides; C, control.
Figure 6. Eﬀect of P and T peptides on the activation of Akt (Ser473) and GSK3 (Ser9). HepG2 cells (1.5 × 105) were treated with 0.5 and 1 mg/mL of
P and T peptides for 24 h, respectively. The phosphorylation levels of Akt (Ser473) (A) and GSK3 (Ser9) (C) and β-actin immunoblotting signals were
detected using speciﬁc anti-posphoAkt (Ser473), anti-posphoGSK3β (Ser9), and anti-β-actin primary antibodies, respectively. PosphoAkt signals (B)
and posphoGSK3β (D) were quantiﬁed by ImageJ software and normalized with β-actin signals. Bars represent averages of duplicate samples± SEM of
three independent experiments. (∗) P < 0.05, (∗∗) P < 0.001, and (∗∗∗) P < 0.0001 versus C. P, pepsin peptides; T, trypsin peptides; C, control; pAkt,
posphoAkt; pGSK3β, posphoGSK3β.
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three diﬀerent experiments, each performed in duplicate, is
shown in Figure 7B. This ﬁgure clearly demonstrates that the
wortmannin co-incubation with P and T peptides is able to
reduce by about 40 and 50% the Akt phosphorylation level,
abolishing the Akt phosphorylation induced by lupin peptides.
To conﬁrm the involvement of the PI3K/Akt pathway
activation in the regulation of the LDLR-SREBP2 pathway,
functional LDL uptake experiments were performed in the
presence of wortmannin. As Figure 7C shows, P peptides and T
peptides are able to increase the LDL uptake with respect to the
basal level, but these uptakes are blocked in the presence of
wortmannin. Precisely, the LDL uptake is blocked at the basal
level either in the presence of the inhibitor alone or in the co-
incubation with P and T peptides, demonstrating that the LDL
uptake induced by lupin peptides is abolished by treatment with
this well-known PI3K inhibitor.
■ DISCUSSION
As already indicated in the Introduction, some experimental
studies11−14 and a few clinical trials17−19 gave clear indications
that lupin proteins are able to induce hypocholesterolemic eﬀects
in vivo. The present investigation at HepG2 cells was aimed at
providing some further information on the mechanism through
which the lupin peptides may be responsible of the observed
activities.
The main ﬁndings of this study are the following: (i) T
peptides are able to directly interfere with the HMGCoAR
activity, whereas P peptides are much less eﬀective. (ii) Both P
and T peptides modulate the cholesterol metabolism at HepG2
cell line, through the up-regulation of the pathway involving
the LDLR. (iii) Both P and T peptide treatments increase the
LDL-uptake. (iv) Activation of the Akt/GSK3β pathway is
involved in the up-regulation of the LDLR-SREBP2 pathway.
HMGCoAR is the rate-controlling enzyme of cellular
cholesterol biosynthesis pathway, and therefore it constitutes
the target of numerous investigations aimed at lowering the rate
of cholesterol biosynthesis.49 Therefore, initially in vitro
experiments were performed using the puriﬁed catalytic domain
of the enzyme with the objective of clarifying whether lupin
peptides were able to directly inhibit the activity of HMGCoAR.
As shown in Figure 3, T peptides but not P peptides act as
enzyme inhibitors.
The LDLR expression and the receptor protein localization at
cellular membranes are strictly correlated to the intracellular
cholesterol biosynthesis pathway. In fact, the transcription of the
LDLR and the genes required for cholesterol and fatty acid
synthesis are controlled by membrane-bound transcription
factors called SREBPs,50 and the intracellular cholesterol acts
with a negative feedback inhibition mechanism.51 The SREBP2
isoform is responsible for the LDLR and HMGCoAR trans-
cription, and the SREBP2 maturation is regulated by the
intracellular cholesterol homeostasis. Thus, the up-regulation
of LDLR represents a useful strategy to control plasma LDL
cholesterol levels. Our ﬁndings demonstrate that both lupin
peptide mixtures are able to up-regulate the LDLR protein levels
through an increase of SREBP2 protein. However, a detailed
investigation of the LDLR pathway revealed that lupin peptides
produce diﬀerent eﬀects on the HMGCoAR level. In particular,
whereas P peptides are able to increase the enzyme protein level
in a dose-dependent manner, T peptides up-regulate the enzyme
protein levels in a signiﬁcantway versus the control at 0.5mg/mL; the
increase remains statistically signiﬁcant, but it is smaller at 1.0mg/mL,
and it is ﬁnally completely abolished at 2.5 mg/mL (Figure 4D).
These pieces of evidence suggest that both peptide mixtures
modulate the cholesterol metabolism pathway through the
induction of LDLR protein levels due to an increase of SREBP2
protein, although their potencies of induction are diﬀerent.
In agreement with immunoblotting results, the increase of
LDLRprotein levels leads to an increase of LDL uptake (Figure 5).
Our ﬁndings suggest that both P and T peptides are able to
signiﬁcantly induce the LDL clearance, and this result is strictly
correlated to an increase of LDLR protein level.
Recently, studies have indicated that there are links between
the Akt and the SREBP pathways: in fact, emerging evidence
Figure 7. Involvement of PI3K/Akt pathway activation in the regulation
of the LDLR−SREBP2 pathway through which lupin peptides mediate
the cholesterol-lowering eﬀects. HepG2 cells (1.5 × 105) were treated
with 1.0 and 0.5 mg/mL of P and T peptides in the presence or absence
of wortmannin for 24 h, respectively. The phosphorylation level of Akt
(Ser473) (A) and β-actin immunoblotting signals were detected using
speciﬁc anti-posphoAkt (Ser473) and anti-β-actin primary antibodies,
respectively. Relative intensity of posphoAkt signals (B) was quantiﬁed
by ImageJ software and normalized with β-actin signals. Panel C shows
the LDL uptake after treatment with the PI3K inhibitor. HepG2 cells
(3 × 104) were treated with P (1.0 mg/mL) and T (0.5 mg/mL)
peptides in the presence or absence of wortmannin and inhibitor alone
for 24 h. LDL-Dylight 549 (10.0 μg/mL) was incubated for additional
2 h. Excess LDL-Dylight 549 was removed, and cells were washed two
times with PBS. Speciﬁc ﬂuorescent LDL uptake was analyzed by
Synergy H1 (Biotek). Bars represent averages of duplicate samples ±
SEM of three independent experiments. pAkt, posphoAkt; P, pepsin
peptides; T, trypsin peptides; C, control.
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shows that Akt is implicated in the regulation of lipid metabolism
through the activation of SREBPs.45,52−55 Luu and co-workers41
showed that insulin-like growth factor-1, an inducer of Akt
signaling, acutely increases SREBP2 activation. This study
provided evidence that Akt contributes to the regulation of
cholesterol metabolism through activating SREBP2.
Even if the precise target or targets of Akt remain elusive and
not clariﬁed, part of our investigation was dedicated to evaluating
the eﬀects of lupin peptides on the PI3K/Akt pathway. Our study
provides experimental evidence that either P or T peptides from
lupin protein are able to induce increases of Akt and GSK3β
phosphorylation levels, which are completely abolished by
treatment with a well-known PI3K inhibitor, such as
wortmannin. A constitutively active form of Akt activated the
LDLR.53 Our ﬁndings clearly support this study, because both P
and T peptides increase the LDLR protein levels and induce an
increased ﬂuorescent LDL uptake at HepG2 cells. Moreover,
after treatment with both lupin peptides in the presence of
wortmannin, LDL uptake is blocked versus the P and T
treatments alone, demonstrating that the inhibition of PI3K/Akt
has general eﬀects on cellular lipid homeostasis, although the
precise Akt target or targets are not deﬁnitely assigned yet.
In conclusion, this is the ﬁrst study providing evidence that
peptide mixtures obtained by the hydrolysis of lupin proteins are
able to modulate the LDLR/SREBP2 pathway with the ﬁnal
eﬀect of an increased LDL uptake. Because, as indicated above,
both P peptides and T peptides are complex mixtures, it appears
very diﬃcult to sort out which may be the peptides responsible
for the observed activities. It is, however, possible to aﬃrm that
the diversity in the behaviors of the two peptide mixtures derives
from their diﬀerent compositions. Further work will be necessary
to investigate these aspects in detail. This is also the ﬁrst study to
investigate in detail the mechanism of the hypocholesterolemic
activity of peptides deriving from a plant protein, because, even in
the case of soy, only partial information is available.26−32
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